Patient Preparation & Study Confounders
What makes a study non-diagnostic or misleading, and why
Quick Answer
A large fraction of non-diagnostic, false-positive, or false-negative studies trace not to disease or hardware but to preparation — the physiologic state of the patient and the drugs they are on. Each preparation step exists because a specific competing substrate, blocking pathway, or physiologic uptake would otherwise degrade or invert the result. This page organizes preparation by the mechanism it controls, so the rationale (not just the rule) is clear — which is what lets you troubleshoot an atypical study.
The Organizing Idea
Preparation manipulates one of four things: substrate competition (glucose vs FDG), pathway blockade (caffeine at adenosine receptors; iodine load at NIS), physiologic uptake (myocardial glucose, brown fat, mucosal washout), or target availability (ER blockers, somatostatin analogs, MIBG-interfering drugs). When a study is atypical, ask which of these was not controlled.
FDG-PET (Oncology)
| Step | Controls | Consequence if omitted |
|---|---|---|
| Fast 4–6 h; glucose < ~150–200 mg/dL | Substrate competition | Hyperglycemia/insulin shift FDG from tumor to muscle → low tumor conspicuity |
| No strenuous exercise ~24 h; warm, quiet | Muscle / brown-fat / laryngeal uptake | Symmetric brown-fat and muscle uptake mimic nodes |
| Consistent uptake time (~60 min) | Quantitative comparability | Invalid serial SUV/PERCIST |
| Hold metformin ~24–48 h (per protocol) | Bowel uptake | Intense bowel activity obscures the abdomen |
| Hydration/void | Urinary activity | Pelvic disease obscured |
Cardiac FDG — Two Opposite Preparations
| Study | Preparation | Rationale |
|---|---|---|
| Cardiac sarcoid | Suppress myocardial glucose (high-fat/very-low-carb, prolonged fast, ± heparin) | Shift myocardium to fatty-acid metabolism so only inflammation lights up |
| Viability | Promote myocardial glucose (glucose load ± insulin / clamp) | Drive FDG into viable myocardium so mismatch is visible |
These are mirror-image preparations — the single most testable preparation concept in cardiac PET. The commonest cause of a non-diagnostic study in either is inadequate glycemic control/preparation.
Vasodilator Stress (MPI)
- Hold caffeine/methylxanthines ~12–24 h — they are competitive adenosine-receptor antagonists and blunt hyperemia (the classic false-negative).
- Aminophylline reverses vasodilator effects; screen for high-grade AV block / bronchospasm.
Thyroid & Iodine Pathway
- Radioiodine therapy (DTC): low-iodine diet, hold iodinated contrast/amiodarone (an amiodarone iodine load persists for months), TSH > 30 (withdrawal or rhTSH), exclude pregnancy/lactation. An uncontrolled iodine load competes at NIS and wastes the therapy — measure urinary iodine if uncertain.
- Thyroid blockade (SSKI/perchlorate) before free-iodide agents: MIBG, radioiodine studies, ioflupane — to protect the thyroid from free iodide.
Target-Availability Blockade
| Agent | Interfering exposure | Effect |
|---|---|---|
| MIBG | Labetalol, tricyclics, sympathomimetics, reserpine | Block NET uptake → false-negative |
| Ioflupane (DAT) | Cocaine, stimulants, some antidepressants | Alter DAT binding |
| FES | Recent tamoxifen/fulvestrant (ER blockers) | False-negative (receptor occupied) |
| DOTATATE | Timing around long-acting somatostatin analogs | Receptor blockade reduces uptake |
Mucosal / GI Preparation
| Study | Step | Rationale |
|---|---|---|
| Meckel | Cimetidine (reduce washout), pentagastrin (uptake), glucagon (peristalsis); perchlorate | Maximize ectopic-gastric-mucosa conspicuity |
| HIDA | Fast ~4 h but not > 24 h (CCK pretreat if TPN/prolonged fast); morphine augmentation; phenobarbital (neonatal atresia) | Avoid a full non-contractile gallbladder (false non-visualization) |
| Gastric emptying | Hold prokinetics/opioids; control glucose; standardized meal; image to 4 h | Drugs and hyperglycemia slow emptying; non-standard meals are non-comparable |
Renal & Therapy Preparation
- Diuretic renography: adequate hydration and bladder emptying/catheterization; stated furosemide timing (F+20/F−15/F0). Dehydration or a full bladder mimic obstruction.
- PRRT (¹⁷⁷Lu-DOTATATE): amino-acid (arginine/lysine) renal-protection infusion (kidneys dose-limiting) + antiemetics (the infusion causes nausea).
- Y-90: the pre-therapy MAA mapping itself is a preparation/safety step (lung-shunt, extrahepatic deposition).
Physical/Technical Preparation
- Brown-fat reduction: warming (and, per protocol, benzodiazepine or beta-blocker).
- Labeled WBC: pair with a sulfur-colloid marrow scan (the incongruence rule) — the "preparation" is the paired study.
- RBC/bleed studies: in-vitro labeling for highest efficiency/lowest free pertechnetate.
- Lymphoscintigraphy: filter the colloid for lymphatic migration.
- MAA: reduce particle number if a large right-to-left shunt is suspected.
Board-Level Synthesis
The two preparations most often confused are cardiac sarcoid (suppress FDG) vs viability (promote FDG), and the two most often forgotten are caffeine hold before vasodilator stress and the iodine load (contrast/amiodarone) before radioiodine. Getting these wrong doesn't just degrade the image — it inverts the clinical conclusion.
When a study is atypical, localize the failure to one of the four levers — substrate competition (glucose/FDG), pathway blockade (caffeine/iodine), physiologic uptake (myocardium/brown fat/mucosal washout), or target availability (ER/somatostatin/MIBG-interfering drugs). This is more useful than a memorized checklist because it lets you reason about drugs and states the checklist never anticipated.
Related Pages
- Reference: FDG-PET preparation & physiologic uptake, quantitative thresholds & decision cutoffs.
- Applied: stress testing, cardiac sarcoidosis, myocardial viability, differentiated thyroid cancer, HIDA, gastric emptying, GI bleeding & Meckel, ¹⁷⁷Lu-DOTATATE.
Figure / Diagram Suggestions
- A four-lever troubleshooting schematic (substrate / pathway / physiologic / target).
- The suppress-vs-promote cardiac-FDG mirror graphic.
Self-Check
Q1. A cardiac FDG study shows diffuse intense myocardial uptake in a sarcoid work-up. What preparation failure explains this and how is it fixed?
Answer: Inadequate myocardial suppression — high-fat/very-low-carb diet, prolonged fast (± heparin) shifts myocardium to fatty-acid metabolism so only inflammation is seen; diffuse uptake usually means failed suppression, not disease.
Q2. A patient scheduled for I-131 therapy had a contrast CT and takes amiodarone. Why defer?
Answer: Both are large iodine loads that compete at NIS and can waste the therapy (amiodarone's load persists for months); confirm a low-iodine state (urinary iodine) first.
Q3. Why hold caffeine before vasodilator stress, and what reverses vasodilator effects if needed?
Answer: Caffeine/methylxanthines are competitive adenosine-receptor antagonists that blunt hyperemia (false-negative); aminophylline reverses vasodilator effects.
Q4. An FES-PET is negative in a patient on fulvestrant. Is the tumor ER-negative?
Answer: Not necessarily — the ER blocker occupies the receptor, causing a false-negative; timing relative to endocrine therapy must be managed.
Evidence & sources
https://nuc.med/patient-preparation-confounders/ Report an issue